DOI:
10.1055/s-00000025
Hormone and Metabolic Research
LinksClose Window
References
Peters S, Gettinger S, Johnson ML. et al.
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).
J Clin Oncol 2017;
35: 2781-2789
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.